United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 3 minute read Pharma Industry News Horizon Therapeutics announces $3.05bn acquisition of Viela Bio to expand rare disease pipeline In a major move to strengthen its leadership in rare diseases, Horizon Therapeutics, an Irish biopharmaceutical company, has… bypharmanewsdailyFebruary 1, 2021